Breaking News Instant updates and real-time market news.

BBBY

Bed Bath & Beyond

$21.50

0.27 (1.27%)

, DAL

Delta Air Lines

$52.86

1.39 (2.70%)

12:15
04/12/18
04/12
12:15
04/12/18
12:15

On The Fly: Top stock stories at midday

Stocks opened sharply higher and tacked on additional gains in the opening hour of trading. Since finding a level, the averages have moved in a narrow range. The move is broad based, as the S&P is up about 1% and the Dow and Nasdaq have gains that are a bit better on a percentage basis. Despite a slight retreat today, the price of WTI crude oil remains just below $67 a barrel. ECONOMIC EVENTS: In the U.S., initial jobless claim fell 9,000 to 233,000 in the week ended April 7. Import prices were flat, with export prices 0.3% higher, in March. COMPANY NEWS: Shares of Bed Bath & Beyond (BBBY) have dropped nearly 20% after the home goods retailer announced better than expected fourth quarter results but issued a weaker 2018 forecast. Following the news, several Wall Street analysts cut their price targets on the stock, while Raymond James analyst Beryl Bugatch downgraded Bed Bath & Beyond to Underperform, a sell-equivalent rating... Meanwhile, shares of airline operator Delta (DAL) are up over 2.5% after the company's earnings beat expectations despite revenue that fell short of the consensus forecast. Commenting on the results and environment, Delta President Glen Hauenstein said the company is seeing its "best revenue momentum since 2014, with positive domestic unit revenues, improvements in all our international entities, strong demand for corporate travel and double-digit increases in our loyalty revenues." MAJOR MOVERS: Among the notable gainers was Incyte (INCY), which gained about 5% after UBS analyst Carter Gould upgraded the stock to Buy from Neutral saying the shares offer an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. Also higher was CB&I (CBI), which advanced almost 12% after the company reported better than expected preliminary Q1 results and McDermott (MDR) said its combination with the former is on track for the second quarter. Among the noteworthy losers was Apogee Enterprises (APOG), which dropped about 10% after the company reported quarterly results and updated FY19 guidance. Also lower were shares of Assembly Biosciences (ASMB), which slid 6% after presenting interim data from Phase 1a and 1b studies of ABI-H0731 in HBV patients. INDEXES: Near midday, the Dow was up 308.60, or 1.28%, to 24,498.05, the Nasdaq was up 71.91, or 1.02%, to 7,140.94, and the S&P 500 was up 23.91, or 0.90%, to 2,666.10.

BBBY

Bed Bath & Beyond

$21.50

0.27 (1.27%)

DAL

Delta Air Lines

$52.86

1.39 (2.70%)

INCY

Incyte

$66.29

-1.83 (-2.69%)

CBI

CB&I

$15.06

1.53 (11.31%)

MDR

McDermott

$6.42

0.42 (7.00%)

APOG

Apogee Enterprises

$42.46

0.01 (0.02%)

ASMB

Assembly Biosciences

$50.29

3.63 (7.78%)

  • 12

    Apr

  • 12

    Apr

  • 12

    Apr

  • 17

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 03

    May

  • 08

    May

  • 30

    May

  • 12

    Jun

  • 29

    Jun

BBBY Bed Bath & Beyond
$21.50

0.27 (1.27%)

04/12/18
RAJA
04/12/18
DOWNGRADE
RAJA
Underperform
Bed Bath & Beyond downgraded to Underperform at Raymond James
04/12/18
LOOP
04/12/18
NO CHANGE
LOOP
Bed Bath & Beyond price target lowered to $18 from $23 at Loop
Loop Capital analyst Anthony Chukumba lowered his price target on Bed Bath & Beyond to $18 from $23 and maintained a Hold rating following the company's "much worse-than-expected" FY18 earnings guidance and subsequent sell-off.
04/12/18
04/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Paycom (PAYC) downgraded to Equal Weight from Overweight at Barclays with analyst Raimo Lenschow saying the stock has meaningfully outperformed over the last year while estimate revisions have been limited. 2. J.B. Hunt (JBHT) downgraded to Sector Weight from Overweight at KeyBanc. 3. Devon Energy (DVN) downgraded to Outperform from Focus List at Scotia Howard Weil. 4. PJT Partners (PJT) downgraded to Hold from Buy at Sandler O'Neill with analyst Sumeet Mody saying after appreciating 17% year-to-date, the stock is approaching fair value. 5. Bed Bath & Beyond (BBBY) downgraded to Underperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
04/12/18
DOWNGRADE

Underperform
Bed Bath & Beyond downgraded to Underperform at Raymond James
As previously reported, Raymond James analyst Beryl Bugatch downgraded Bed Bath & Beyond to Underperform from Market Perform following quarterly results. Despite the array of initiatives announced by management, a key issue for the analyst is that the fleet of over 1,000 legacy Bed Bath & Beyond stores continue to deliver in-store mid-single-digit comp sales declines. Without some underlying growth in management generated earnings over the next two years, shareholder value is likely to erode further, he adds. Nonetheless, Bugatch points out that at its current valuation, Bed Bath may attract "activist" interest.
DAL Delta Air Lines
$52.86

1.39 (2.70%)

04/05/18
STFL
04/05/18
NO CHANGE
Target $100
STFL
Buy
Delta Air Lines price target raised to $100 from $90 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $100 from $90 on valuation. The analyst reiterates a Buy rating on the shares given Delta's combination of peer-leading operating margins, an investment grade balance sheet, structural advantages related to the location of its hubs and greater labor flexibility.
03/09/18
JPMS
03/09/18
NO CHANGE
JPMS
JPMorgan sees Airlines raising Q1 outlooks at next week's conference
JPMorgan analyst James Baker believes several Airlines will raise their Q1 guidance at his firm's Aviation, Transportation and Industrials Conference next week. He expects near-term consensus estimates to move higher for the airlines coming out of the presentations, particularly for United Continental (UAL). The analyst recommends increasing exposure to the sector ahead of the conference. He raised his estimates for United the most, taking his Q1 earnings per share forecast up to 32c from 3c. Other names in the space include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU) and Southwest (LUV).
02/28/18
STFL
02/28/18
NO CHANGE
Target $90
STFL
Buy
Delta Air Lines price target raised to $90 from $85 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $90 after reviewing the company's annual filing. The price target represents a new high on the Street, according to Bloomberg. The analyst cites stronger growth from Delta's loyalty program for the target raise. His sum-of-the-parts analysis values the core airline at seven times 2019 earnings and the loyalty program at 22 times. DeNardi keeps a Buy rating on Delta Air Lines.
01/26/18
COWN
01/26/18
NO CHANGE
COWN
Airline sector weakness a buying opportunity, says Cowen
Cowen analyst Helane Becker noted airline stocks came under pressure as investors grew concerned about capacity growth by United Continental (UAL) and fears it would destroy the fare structure. The analyst noted the capacity growth is in small markets where they might make a difference but that RASM is up year-over-year. Becker would be a buyer of Alaska Air (ALK), Delta Air (DAL), American Airlines (AAL) and Southwest Air (LUV) on the pullback, but would avoid United Continental shares.
INCY Incyte
$66.29

-1.83 (-2.69%)

04/10/18
MZHO
04/10/18
NO CHANGE
Target $27
MZHO
Buy
Concert still likely to win IPR challenge against Incyte, says Mizuho
Mizuho analyst Difei Yang does not see a read-through to the final decision from the Patent Trial and Appeal Board's granting Incyte's (INCY) motion for reconsideration as it relates to the Inter Partes Review Petition challenge against Concert Pharmaceuticals (CNCE). The analyst still thinks Concert is likely to win the challenge based on how it has defended its patents historically. The company has an "impressive track record" on intellectual protection front, Yang tells investors in a research note. The analyst reiterates a Buy rating on Concert Pharmaceuticals with a $27 price target. The stock in morning trading is down 5%, or 96c, to $19.08.
04/09/18
04/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 2. Mettler-Toledo (MTD) downgraded to Neutral from Buy at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools but is more cautious on the outlook for sales upside at Mettler given his view of a likely moderation of growth in China after a year of catch-up investment in the region. Donnelly also highlights "tough comps" in Labs and Product inspection. 3. Franklin Resources (BEN) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier saying Franklin's bottom half performance and continued outflows limits organic growth and multiple expansion. 4. NewLink Genetics (NLNK) downgraded to Neutral from Overweight at Cantor Fitzgerald and Baird as well as to Hold from Buy at Jefferies. 5. Incyte (INCY) downgraded to Hold from Buy at Gabelli with analyst Jing He citing the "surprising" failure of the Phase 3 ECHO-301 study in melanoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
UBSW
04/12/18
UPGRADE
Target $76
UBSW
Buy
Incyte upgraded to Buy from Neutral at UBS
UBS analyst Carter Gould upgraded Incyte (INCY) to Buy while lowering his price target for the shares to $76 from $106. The stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models, Gould tells investors in a research note. The focus on epacadostat "obscured an otherwise solid, profitable, and strategically attractive Jakafi franchise," the analyst contends. He believes the base business alone supports $65 per share, even before considering its "compelling strategic attractiveness." Incyte closed yesterday down $1.83 to $66.29. Gould thinks clinical catalysts against low expectations can drive $13-$17 per share of upside over 2018.
CBI CB&I
$15.06

1.53 (11.31%)

01/24/18
KEYB
01/24/18
UPGRADE
Target $14
KEYB
Overweight
McDermott upgraded to Overweight with $14 target at KeyBanc
KeyBanc analyst Tahira Afzal upgraded McDermott (MDR) to Overweight from Sector Weight with a $14 price target. The analyst expects a "step-up in execution" at CB&I (CBI) following the merger and has confidence in a sustained improvement in the energy macro environment. He believes the deal will create value.
12/20/17
MSCO
12/20/17
NO CHANGE
MSCO
Underweight
McDermott may have hard time recognizing CB&I synergies, says Morgan Stanley
Morgan Stanley analyst Ole Slorer said he sees room for concern over McDermott's (MDR) deal to combine in an all-stock transaction with CB&I (CBI). McDermott's "pristine" balance sheet and improved execution could be hurt by CBI's recent execution challenges and "higher than optimal" debt, while synergies from the merger may be difficult to realize, contends Slorer, who keeps an Underweight rating on McDermott shares.
12/19/17
MACQ
12/19/17
UPGRADE
MACQ
Neutral
CB&I upgraded to Neutral from Underperform at Macquarie
CBI (CBI) is being acquired by McDermott International (MDR).
12/19/17
DADA
12/19/17
DOWNGRADE
Target $19
DADA
Neutral
CB&I downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Brent Thielman downgraded CB&I (CBI) to Neutral from Buy and lowered his price target to $19 from $25 after the company entered into a merger agreement with McDermott International (MDR). Thielman says that CB&I's execution challenges reduce the likelihood of a competitive bid, adding that he expects the deal to pass regulatory requirements.
MDR McDermott
$6.42

0.42 (7.00%)

01/23/18
KEYB
01/23/18
UPGRADE
KEYB
Overweight
McDermott upgraded to Overweight from Sector Weight at KeyBanc
APOG Apogee Enterprises
$42.46

0.01 (0.02%)

04/04/18
GSCO
04/04/18
DOWNGRADE
Target $39
GSCO
Sell
Apogee Enterprises downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Samuel Eisner downgraded Apogee Enterprises to Sell and cut his price target for the shares to $39 from $44. The analyst believes "cyclical maturity" and margin risk warrant caution on the shares. Goldman expects private non-residential construction growth to flatten in 2018 and 2019, which makes Apogee's returns outlook less attractive relative to peers, Eisner tells investors in a research note.
08/24/17
DADA
08/24/17
NO CHANGE
DADA
Apogee Enterprises weakness overdone, says DA Davidson
DA Davidson analyst Brent Thielman says that the reduction in Apogee's fiscal 2018 guidance "raises concerns" about its "M&A and mid-size glass market penetration strategies." However, the analyst thinks that the weakness in the stock was overdone, and he remains upbeat on the company's fiscal 2019 outlook. The analyst cut his price target on the stock to $52 from $65 but keeps a Buy rating on the shares.
05/25/17
SIDC
05/25/17
INITIATION
SIDC
Buy
Apogee Enterprises re-initiated with a Buy at Sidoti
04/17/17
CHLM
04/17/17
NO CHANGE
Target $68
CHLM
Buy
Apogee Enterprises pullback creates buying opportunity, says Craig-Hallum
Craig-Hallum analyst Eric Stine notes that Apogee Enterprises reported "solid 4Q results," but points out that the pullback on misplaced concerns over non-re construction cycle due to 2018 revenue guidance creates a buying opportunity. The analyst reiterates a Buy rating and $68 price target.
ASMB Assembly Biosciences
$50.29

3.63 (7.78%)

04/12/18
JEFF
04/12/18
NO CHANGE
Target $75
JEFF
Buy
New data from Assembly Biosciences look 'great,' says Jefferies
Assembly Biosciences presented this morning positive detailed results from its Phase IB study of oral ABI-H0731 in chronic hepatitis B patients, Jefferies analyst Michael Yee tells investors in a research note titled "New EASL Data Looks Great - Potent Efficacy Across HBV Populations - BUY." He believes the data show potent efficacy and dose response across hepatitis B patients as well as clean safety and tolerability. The analyst thinks Assembly "will increasingly be getting on the map" of big pharma and large biotech. The company remains an attractive takeover candidate for big companies in the anti-viral space as its drugs are "starting to play out," Yee contends. He keeps a Buy rating on Assembly Biosciences with a $75 price target.
03/08/18
JEFF
03/08/18
NO CHANGE
Target $75
JEFF
Buy
Assembly Biosciences price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for Assembly Biosciences to $75 and keeps a Buy rating on the shares. The analyst continues to like Assembly as a top smid-cap biotech idea given "emerging promising data" for core protein inhibitors in Hepatitis B, its "own strong and growing" pipeline with data catalysts this year, and "significant" market opportunity. Further, the analyst sees the company's $120M cash position as sufficient to move beyond 2018 and fund large Phase II studies.
01/15/18
JEFF
01/15/18
NO CHANGE
Target $50
JEFF
Buy
Assembly Biosciences offers 'compelling' upside opportunity, says Jefferies
Jefferies analyst Michael Yee says Assembly Biosciences offers a "compelling asymmetric upside opportunity" given the company's potential for a functional cure in a multi-billion dollar opportunity in Hepatitis B. The analyst thinks Assembly's upcoming Phase IB data should show "positive and potent" antiviral responses and clean safety, further de-risking the program into Phase II. Yee keeps a Buy rating on the shares with a $50 price target.
01/05/18
RILY
01/05/18
INITIATION
Target $35
RILY
Neutral
Assembly Biosciences initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Assembly Biosciences with a Neutral rating and $35 price target.

TODAY'S FREE FLY STORIES

IVC

Invacare

$16.50

0.15 (0.92%)

21:30
08/15/18
08/15
21:30
08/15/18
21:30
Downgrade
Invacare rating change  »

Invacare downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change  »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated at UBS »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated at UBS »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated at UBS »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated at UBS »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated at UBS »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated at UBS »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated at UBS »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated at UBS »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated at UBS »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated at UBS »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated at UBS »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated at UBS »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated at UBS »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$84.51

-1.6 (-1.86%)

18:55
08/15/18
08/15
18:55
08/15/18
18:55
Initiation
Spirit AeroSystems initiated at UBS »

Spirit AeroSystems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$351.43

-5.195 (-1.46%)

18:54
08/15/18
08/15
18:54
08/15/18
18:54
Initiation
TransDigm initiated at UBS »

TransDigm initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$240.82

-2.5 (-1.03%)

18:54
08/15/18
08/15
18:54
08/15/18
18:54
Initiation
Huntington Ingalls initiated at UBS »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.